MDxHealth is trading at $0.20, down 9.22%, with no confirmed fresh company catalyst identified.
- The latest company release, dated October 15, reported preliminary Q3 revenue of $22.7 million and suspended 2026 revenue guidance.
- Broader risk-off trading may be adding pressure; the supplied market context shows the S&P 500 down 1.38% and Nasdaq down 2.31%.
- The earlier guidance suspension and analyst downgrades are relevant background, not confirmed fresh catalysts for this move.